Ionis Pharmaceuticals (MEX:IONS) Long-Term Debt: MXN24,330 Mil (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
67 GF Score
Price MXN1,150.00
GF Value MXN757.76
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Long-Term Debt?

Ionis Pharmaceuticals MEX:IONS 67 Long-Term Debt is MXN24,330 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 67/100 and a GF Value™ of MXN757.76. The stock has 8 warning signs investors should review.

Ionis Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was MXN24,330 Mil.

Ionis Pharmaceuticals's quarterly Long-Term Debt increased from Sep. 2025 (MXN10,931 Mil) to Dec. 2025 (MXN24,262 Mil) and increased from Dec. 2025 (MXN24,262 Mil) to Mar. 2026 (MXN24,330 Mil).

Ionis Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 (MXN20,870 Mil) to Dec. 2024 (MXN25,975 Mil) but then declined from Dec. 2024 (MXN25,975 Mil) to Dec. 2025 (MXN24,262 Mil).

Ionis Pharmaceuticals  (MEX:IONS) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ionis Pharmaceuticals Long-Term Debt Related Terms

Ionis Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Long-Term Debt Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25,193.08 23,058.29 20,869.86 25,975.46 24,261.65

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25,587.44 11,777.55 10,931.46 24,261.65 24,330.42
MEX:IONS
67GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN24,330 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Long-Term Debt of MXN24,330 Mil as of Mar. 2026.
Is Ionis Pharmaceuticals' Long-Term Debt too high?
Ionis Pharmaceuticals' current Long-Term Debt is MXN24,330 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Long-Term Debt compare to EXEL and BBIO?
Ionis Pharmaceuticals' Long-Term Debt of MXN24,330 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ionis Pharmaceuticals's current Long-Term Debt is MXN24,330 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Long-Term Debt of MXN24,330 Mil. The stock's GF Value™ is MXN757.76, compared to a current price of MXN1,150.00 — trading 51.8% above its estimated fair value. The current Long-Term Debt is MXN24,330 Mil. Ionis Pharmaceuticals' overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Long-Term Debt is MXN24,330 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 51.8% above its estimated GF Value™ of MXN757.76.

Key valuation signals for MEX:IONS:

  • Long-Term Debt: MXN24,330 Mil
  • GF Value™: MXN757.76 vs. price of MXN1,150.00 (51.8% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
67GF Score

Get the complete analysis for MEX:IONS

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN757.76
GF Value